Index

73T strain, Newcastle disease virus 356
“aberrant” arteries 14
abscesses, cryoablation and 228, 235 (Table)
“accessory” arteries 14–15, 80 (Fig.)
acetic acid ablation 127, 267
clinical results 272
dosage 268
acini 30
acquired immune deficiency syndrome see human immunodeficiency virus infection
activated clotting time, isolated hepatic perfusion 164
activated partial thromboplastin time (APTT) on-site monitoring 525–7
for percutaneous ethanol injection 269
acupoints 415
acupuncture 417
acute cholinergic syndrome 107
ACVBP (chemotherapy regimen), post-transplant lymphoproliferative disorders 465
adenoma, hepatic
computed tomography 81
magnetic resonance imaging 94 (Fig.)
pregnancy 467
transplantation and 285–6
adenovirus 354 (Table), 356–60, 408
adhesions, repeat liver resection 216
adjuvant therapy
chemotherapy
breast carcinoma metastases 446
cholangiocarcinoma 187
colorectal carcinoma metastases 110–11, 158, 159 (Table), 196, 344–5
see also preoperative chemotherapy
HCC 296–303
cost-effectiveness 536
retinoids 297 (Table), 299–300, 387–8
transarterial chemoembolization as 147
see also bridging therapy
adoptive transfer, lymphocytes 300
Adriamycin see doxorubicin
alatoxin
HCC 54, 489, 515
p53 gene mutations 371, 515
Africa 509–18
afterloading, radionuclide therapy 126
age
cholangiocarcinoma incidence 57
colorectal carcinoma metastases 193–4
HCC 52
Africa 509–10
China 510
hepatitis B and C viruses, Africa 510
hepatitis C virus vs hepatitis B virus infections 510, 515
liver resection 310
see also elderly people
genesis of gallbladder 22
AIDS see human immunodeficiency virus infection
Akt (protein) 374, 386–7
alcohol
cholangiocarcinoma 58, 59, 60, 72
HCC 53–4
Africa 515
Brazil 505
see also ethanol ablation
alcoholic steatohepatitis 30–1, 32
algorithms 307
for assessment
HCC detection, Japan 490, 491 (Fig.)
perioperative cardiac 458–9
for treatment
Barcelona Clinic Liver Cancer staging system 319 (Fig.)
cholangiocarcinoma 325 (Fig.), 327 (Fig.), 329 (Fig.)
colorectal carcinoma metastases 343 (Fig.)
gallbladder carcinoma 338–9
Japan 320 (Fig.)
HCC 494 (Fig.)
liver resection in cirrhosis 309 (Fig.)
perioperative coronary intervention and 459 (Table), 460 (Table)
see also clustering algorithms
alkali therapy, percutaneous 277
alkaline phosphatase see liver function
allocation policies, transplantation for HCC 288–9
alpha-1-antitrypsin
deficiency, cholangiocarcinoma 60
fibrolamellar HCC 41
alpha-fetoprotein 43, 69–71
diagnosis 70
HCC 71
Africa 513
Asia 489–90
cost-effectiveness of screening 534
postoperative follow-up 222
hepatoblastoma 477, 481
L3 fraction, HCC surveillance 490
prognosis 127
promoters for gene therapy 354–5, 357
treatment monitoring 70–1
alpha-L-fucosidase 71
alternating current, heating by 244–6
alternative medicine 414–17, 419
altitude, implantable infusion pump flow rates 151
American Joint Committee on Cancer, staging of gallbladder carcinoma 335–6
amplicons, herpes simplex type 1 virus 360–3
amplifications, chromosomal, HCC 370
anatomic resections 181
colorectal carcinoma metastases 194
segment 1 183
anatomy 11–26, 177–8
blood supply 131
see also specific blood vessels
historical aspects 4
nomenclature 5, 177–8
pathological distortions 22
regeneration of liver on 216
anesthesia
liver surgery 519–30
induction and maintenance 522, 523
percutaneous ethanol injection 268
anesthetic agents, hepatic clearance 522 (Table)
angioembolization 400–4
inhibitors 349, 376–8, 388–9, 400–13
cost-effective 400–4
conventional treatment combined with 409
see also specific drugs
liver as environment for 402
tumor growth 401–2
angiogenic barrier concept 410
angiogenic switch 400
angiography 93–5, 97 (Fig.)
angioma 439
computed tomography 79–80
internal radiotherapy 132
percutaneous hepatic perfusion 169
selective continuous intra-arterial chemotherapy 152
transarterial embolization 142
angipoiotin-2, HCC 402
angiosarcoma 46, 439–41, 482
chemotherapy 116, 440
transplantation for 291, 440
angioandin 407–8
doxorubicin with 409
animal models, molecular targeted therapies 374
anomalies
bile ducts 15–16
extrahepatic 23–4

gallbladder carcinoma 333–4
left hemiliver drainage 16
right hemiliver drainage 15–16
cystic artery 23
gallbladder 22
hepatic artery 24, 152
of origin 14 (Fig.)
portal vein 18
antennae, microwave thermal ablation 254, 255,
animal models, molecular targeted therapies 374
angiostatin 407–8
Index
Argentina
Aretxabala, Xabier de, on gallbladder carcinoma
arantian plate 21
Areatxaba, Xabier de, on gallbladder carcinoma
invasion 504
Argentina
metastases 505
colorectal carcinoma 505
transplantation 501, 505
see also River Plate school
arginine deiminase 404 (Table)
argon, for cryoablation 230
argon beam coagulation, gas embolism 204
Arrow implantable infusion pumps 151, 153
arterialization 33
arteries see blood vessels; named arteries
ascites
hemorrhagic 97 (Fig.)
liver resection planning 179
open vs laparoscopic liver resection 210
Asia 487–99
interferon side-effects 298–9
living donor liver transplantation 492–3
HCC and 288
sorafenib trial 385–6
aspartate, thrombocytopenia 233
atelectasis, cryoablation 233
atracurium, liver transplantation 523
atrophy, gastric, chronic 425
autopsy, liver weight, Africa 511
autotransfusion, liver transplantation 523
awareness, anesthesia 522
AXIN1 mutations 388
Ayurveda 414–15
AZD2171 (Recentin) 110, 404 (Table)
B4 (bile duct), anomalies 16
bacteria, gallbladder carcinoma 503
Bad (protein), underexpression 396
Bantu visceral siderosis 515
Barcelona Clinic Liver Cancer staging system 139, 140 (Fig.), 317, 318
Japanese guidelines vs 320–1
treatment algorithm 319 (Fig.)
bare area 21
bare crease 21
basic fibroblast growth factor, HCC 402
batimastat 408
Bax (protein), underexpression 396
BAY12–9566 (selective MMPI) 408–9
Bcl-2 (protein)
antisense oligonucleotides 397
overexpression 396
Beckwith-Wiedemann syndrome 475
Berkholt system, radiofrequency ablation 247
Bernardino needle 268
beta-blockers, perioperative 459
beta-catenin
cholangiocarcinoma 61
HCC 388
see also Wnt signaling pathway
beta emission, radioconjugates 132 (Table)
bevacizumab 404 (Table), 405–6
BCL2 overexpression 396
Bcl-2 (protein)
antisense oligonucleotides 397
overexpression 396
BilIN
biliary tract carcinoma 115
breast carcinoma metastases 406
colorectal carcinoma metastases 108–9, 197, 405
neoadjuvant 344
HCC 112, 113, 349, 376, 377 (Table), 388
erlotinib with 376, 389
liver resection and 115, 310, 406
pancreatic endocrine tumors 115
renal cell carcinoma metastases 406
 bile duct system (biliary tract)
anastomosis, high biliary-enteric 16
anatomy 15–16
extrahepatic 23–4
intrahepatic 11
liver regeneration on 216
anomalies 15–16
extrahepatic 23–4
gallbladder carcinoma 333–4
left hemiliver drainage 16
right hemiliver drainage 15–16
blood supply 24–5
bypass, segment 3 bile duct 16
carcinoma
systemic therapy 113–15
see also cholangiocarcinoma; gallbladder, carcinoma
caudate lobe 16–17
colorectal carcinoma metastases 48, 111
cystadenocarcinoma 45–6
cysts, cholangiocarcinoma and 57 (Table), 58
excision 337
fibrosis of liver due to diseases of 33
fistula, after cryoablotion 235 (Table)
preoperative catheterization, cholangiocarcinoma resection 186, 312, 328
radioembolization toxicity 134
strictures
gelfoam embolization 142
radiofrequency ablation and 252
see also cholangiography; common bile duct bile salt transporter proteins,
cholangiocarcinoma 61
biliary cystadenocarcinoma 45–6
biliary-enteric anastomosis, high 16
biliary fistula, after cryoablotion 235 (Table)
biliary intraepithelial neoplasia (BilIN) 61
biliary papillomatosis
cholangiocarcinoma and 57 (Table), 60
see also intraductal cholangiocarcinoma
biliary tract see bile duct system
bilirubin, liver resection planning 179
bilomas 23
at cryosites 240
biopsy 474
angiosarcoma 439
fatty liver disease 31
HCC 282
hepatoblastoma 479
hilar cholangiocarcinoma 326
Kaposi sarcoma 462
neuroendocrine tumors 427
post-transplant lymphoproliferative disorders 465
seeding and 282
bioterrorism, neuroendocrine tumors 427–8
Bismuth classification, hilar cholangiocarcinoma 326
Bismuth, Henri 6
“blind” instruments, laparoscopic liver transection 206–7
blood loss
inferior vena cava pressure 525 (Fig.)
resection of liver 180
laparoscopic 208
blood salvage, liver transplantation 523
blood supply 131
bile ducts 24–5
by hepatic artery 11–12
see also vascularity of tumors
blood vessels
cryotherapy 228
as heat sinks 228, 245–6
sealing system, laparoscopic liver transection 206
see also vascularity of tumors
body mass index, HCC mortality 54
body surface area, total liver volume vs 198
boiling carboplatin 275
bone marrow
hepatoblastoma 477
radiation dose limitation 134
differentiation, as criterion for transplantation 284

diffuse HCC 40
diffusers, laser thermal ablation 259
direct cholangiography 97, 98 (Fig.)
computed tomography with, hilar cholangiocarcinoma 82
DISCs (defective infection single-cycle HSVs) 360, 361
Disse, space of 30, 31 (Fig.)
disseminated intravascular coagulation, adenoviruses 360
dissemination see seeding of tumor
distal cholangiocarcinoma 324, 328–30
distal intrahepatic selective embolization, hepatic artery, neuroendocrine tumors 433
dl1520 (genetically engineered adenovirus) 357–60
dlsptk (HSV mutant), oncolytic therapy 361
dobutamine stress electrocardiography, for liver transplantation 521
donor livers
preservation 6
steatosis 7
donor-origin post-transplant lymphoproliferative disorders 465
DOPA, 11C-labeled, PET, neuroendocrine donor livers
deoxyadenosine, low-dose 523
dexamethasone, low-dose 259
dexilbofuram, polymeric Microspheres 151
Doppler ultrasound 76
dorsal resection 183, 184 (Fig.)
dorsal sector of liver 177
dosage
acetate acid ablation 268
isolated hepatic perfusion, maximum tolerated 165
dose calculation
internal radiotherapy 133
see also radiation dose limitations
dose–response curves, cytotoxic drugs 155
dose–volume histograms (DVH) 123, 126 (Fig.)
safe doses 128
double-contrast MRI 90–1
double gallbladder 22
double-stranded protein kinase, oncolytic therapy 355
doubling times
colorectal carcinoma metastases 65–6
HCC 54
Africa 512
downstaging 285
colorectal carcinoma metastases 111–12
see also under transplantation
doxorubicin (Adriamycin)
angiotatin with 409
HCC 112, 377 (Table)
cetuximab with 383
isolated hepatic perfusion 167
sorafenib with 386
neuroendocrine tumors, chemoembolic therapy 434
pancreatic endocrine tumors, streptozocin
with 115
RAD001 with 387
drainage (surgical)
bile duct system, cholangiocarcinoma resection 186, 312, 328
liver resection 181, 186
dropout, transplantation waiting lists 286
see also bridging therapy
drug-eluting beads (DEB) 146
drugs
hepatic clearance 522 (Table)
interactions with herbal remedies 416
prodrugs, suicide gene prodrug therapy 353
dual loop probes, microwave thermal ablation 255
dual-regulated oncolytic adenovirus
CNHK500 357
“ducts of Luschka” 23
duodenum, primary neuroendocrine tumors 425
duration of freezing 227
dye injection, selective continuous intra-arterial chemotherapy 152
dynamic positron emission tomography, ethanol in tumors 267
dysplasia–carcinoma sequence, cholangiocarcinoma 61, 62 (Fig.)
dysplastic nodules 41
e antigen negativity, hepatitis B virus 515
ELK gene, oncolytic therapy 357
E1B-55K-encoding gene 357
Eastern Cooperative Oncology Group (ECOG), performance status 132
ECF regimen, biliary tract carcinoma 114
echinococcosis, computed tomography 80–1
echocardiography 521 (Table)
transesophageal 523, 527
economics 534–7
edges see margins
elderly people, resection of liver 460–1
electrical heating 244
electrical stimulation, for pruritus 417
electrocardiography 456–7
epiplakin, histopathology 157
epidermatitis 29
epidermal growth factor receptor (EGFR) 349, 369, 373, 376, 382–3
cetuximab on 109, 376
panitumumab and 109–10
transforming growth factor α on 374
epidermal angiogenesis, thoracic 522
epinephrine, intralesional chemotherapy 275
epirubicin, pancreatic endocrine tumors 115
epithelial hepatoblastoma 43–4
epitheloid hemangioendothelioma 46–7, 441–2
chemotherapy 116
transplantation for 291, 442
epsilon-aminocaproic acid, liver transplantation 524
Epstein-Barr virus
non-Hodgkin lymphoma 463
post-transplant lymphoproliferative disorders 464
p-ERK (MAPK pathway activation marker) 374
erlotinib
as antiangiogenic agent 404 (Table)
colorectal carcinoma metastases 110
HCC 113, 373, 376, 377 (Table), 383
bevacizumab with 376, 389
sorafenib with 386
Escherichia coli, lacZ gene mutation, gene therapy 362
Essiac (herbal remedy) 416
estimated total liver volume 198
ethanol ablation 127, 266–72
clinical results 271–2
colorectal carcinoma metastases, recurrence after liver resection 220
in combination therapies 274–5
complications 269–70
HCC 251, 321
recurrent 223
metastases 220, 275
in multiblalation therapy 275
embryonal sarcoma 47
encephalopathy 519–20
docrine tumors see neuroendocrine tumors
dogenous antiangiogenic compounds 407–8
dogenous opioids, acupuncture and 417
edoscopic stenting, cholangiocarcinoma, costs 536
edoscopic ultrasound
gallbladder carcinoma 334
hilar cholangiocarcinoma 326
endostatin 408
endothelial cells 400
antibody-mediated vascular targeting 409
HCC 402
sinusoidal 404
VEGF as survival factor 405
endpoints, clinical trials 375
energy requirements, cardiovascular status 457 (Table)
esinophilic globules, embryonal sarcoma 47
epithelial plexus 24
epidemiology 29
colorectal carcinoma metastases 64–5
HCC 52
epidermal growth factor inhibitors 406–7
epidermal growth factor receptor (EGFR) 349, 373, 376, 382–3
cetuximab on 109, 376
panitumumab and 109–10
transforming growth factor α on 374
epidermal angiogenesis, thoracic 522
epinephrine, intralesional chemotherapy 275
epirubicin, pancreatic endocrine tumors 115
epithelial hepatoblastoma 43–4
epitheloid hemangioendothelioma 46–7, 441–2
chemotherapy 116
transplantation for 291, 442
epsilon-aminocaproic acid, liver transplantation 524
Epstein-Barr virus
non-Hodgkin lymphoma 463
post-transplant lymphoproliferative disorders 464
p-ERK (MAPK pathway activation marker) 374
erlotinib
as antiangiogenic agent 404 (Table)
colorectal carcinoma metastases 110
HCC 113, 373, 376, 377 (Table), 383
bevacizumab with 376, 389
sorafenib with 386
Escherichia coli, lacZ gene mutation, gene therapy 362
Essiac (herbal remedy) 416
estimated total liver volume 198
ethanol ablation 127, 266–72
clinical results 271–2
colorectal carcinoma metastases, recurrence after liver resection 220
in combination therapies 274–5
complications 269–70
HCC 251, 321
recurrent 223
metastases 220, 275
in multiblalation therapy 275
Index

gastritis, chronic atrophic 425
gastroduodenal artery, selective continuous intra-arterial chemotherapy 152
gastroenteropancreatic NETs, chemotherapy 116
gastrointestinal tract complications of radioembolization 135
post-transplant lymphoproliferative disorders 464
primary neuroendocrine tumors 424–5
gemcitabine 376
gelfoam 142
hemostasis, cryoablation 231
gemcitabine
cholangiocarcinoma 114
adjunctive chemotherapy 187
mitomycin with 114
gallbladder carcinoma 188
HCC, oxaliplatin with 112–13, 376, 377
(Table)
pancreatic endocrine tumors and 115
cholangiocarcinoma 333, 502
HCC incidence 52, 488
Africa 509
gene expression dysregulation 371–2
gene expression profiling, selection criterion for transplantation 284
gene therapy
HCC, adjuvant 297 (Table), 300
viral-based 361
angiotatin 408
generators
microwave thermal ablation 254
radiofrequency ablation 245, 246
genetics
cholangiocarcinoma 60–1
colorectal carcinoma metastases 67
HCC, etiology 52–3, 368–74
genomic analyses 349–50
clustering algorithms 371
see also microarray technologies
geography
HCC 52, 487–8
hepatitis C virus 514
Germany
minimum procedure volumes 532
quality measurements 531
gestational immunosuppression 468
gimeracil 110
Gli (protein), Hedgehog pathway signaling on 372
Glisson, Francis (17th century) 3
glucagonomas 426
cancer therapy 433
glycoprotein(s), cell line for DISC-HSV
allogeneic 462
glycoprotein H, cell line for DISC-HSV
HCC 487–8
 treeNodeing 371
adjunctive chemotherapy 187
mitomycin with 114
cholangiocarcinoma 188
HCC, oxaliplatin with 112–13, 376, 377
(Table)
pancreatic endocrine tumors and 115
cholangiocarcinoma 333, 502
HCC incidence 52, 488
Africa 509
gene expression dysregulation 371–2
gene expression profiling, selection criterion for transplantation 284
gene therapy
HCC, adjuvant 297 (Table), 300
viral-based 361
angiotatin 408
generators
microwave thermal ablation 254
radiofrequency ablation 245, 246
genetics
cholangiocarcinoma 60–1
colorectal carcinoma metastases 67
HCC, etiology 52–3, 368–74
genomic analyses 349–50
clustering algorithms 371
see also microarray technologies
geography
HCC 52, 487–8
hepatitis C virus 514
Germany
minimum procedure volumes 532
quality measurements 531
gestational immunosuppression 468
gimeracil 110
Gli (protein), Hedgehog pathway signaling on 372
Glisson, Francis (17th century) 3
glucagonomas 426
cancer therapy 433
glycoprotein(s), cell line for DISC-HSV
allogeneic 462
glycoprotein H, cell line for DISC-HSV
HCC 487–8
 treeNodeing 371
adjunctive chemotherapy 187
mitomycin with 114
cholangiocarcinoma 188
HCC, oxaliplatin with 112–13, 376, 377
(Table)
pancreatic endocrine tumors and 115
cholangiocarcinoma 333, 502
HCC incidence 52, 488
Africa 509
gene expression dysregulation 371–2
gene expression profiling, selection criterion for transplantation 284
gene therapy
HCC, adjuvant 297 (Table), 300
viral-based 361
angiotatin 408
generators
microwave thermal ablation 254
radiofrequency ablation 245, 246
genetics
cholangiocarcinoma 60–1
colorectal carcinoma metastases 67
HCC, etiology 52–3, 368–74
genomic analyses 349–50
clustering algorithms 371
see also microarray technologies
geography
HCC 52, 487–8
hepatitis C virus 514
Germany
minimum procedure volumes 532
quality measurements 531
gestational immunosuppression 468
gimeracil 110
Gli (protein), Hedgehog pathway signaling on 372
Glisson, Francis (17th century) 3
glucagonomas 426
cancer therapy 433
glycoprotein(s), cell line for DISC-HSV
allogeneic 462
glycoprotein H, cell line for DISC-HSV
HCC 487–8
 treeNodeing 371
adjunctive chemotherapy 187
mitomycin with 114
cholangiocarcinoma 188
HCC, oxaliplatin with 112–13, 376, 377
(Table)
pancreatic endocrine tumors and 115
cholangiocarcinoma 333, 502
HCC incidence 52, 488
Africa 509
gene expression dysregulation 371–2
gene expression profiling, selection criterion for transplantation 284
gene therapy
HCC, adjuvant 297 (Table), 300
viral-based 361
angiotatin 408
generators
microwave thermal ablation 254
radiofrequency ablation 245, 246
genetics
cholangiocarcinoma 60–1
colorectal carcinoma metastases 67
HCC, etiology 52–3, 368–74
genomic analyses 349–50
clustering algorithms 371
see also microarray technologies
geography
HCC 52, 487–8
hepatitis C virus 514
Germany
minimum procedure volumes 532
quality measurements 531
gestational immunosuppression 468
gimeracil 110
Gli (protein), Hedgehog pathway signaling on 372
Glisson, Francis (17th century) 3
glucagonomas 426
cancer therapy 433
glycoprotein(s), cell line for DISC-HSV
allogeneic 462
glycoprotein H, cell line for DISC-HSV
HCC 487–8
 treeNodeing 371
adjunctive chemotherapy 187
mitomycin with 114
cholangiocarcinoma 188
HCC, oxaliplatin with 112–13, 376, 377
(Table)
pancreatic endocrine tumors and 115
cholangiocarcinoma 333, 502
HCC incidence 52, 488
Africa 509
gene expression dysregulation 371–2
gene expression profiling, selection criterion for transplantation 284
gene therapy
HCC, adjuvant 297 (Table), 300
viral-based 361
angiotatin 408
generators
microwave thermal ablation 254
radiofrequency ablation 245, 246
genetics
cholangiocarcinoma 60–1
colorectal carcinoma metastases 67
HCC, etiology 52–3, 368–74
genomic analyses 349–50
clustering algorithms 371
see also microarray technologies
geography
HCC 52, 487–8
hepatitis C virus 514
Germany
minimum procedure volumes 532
quality measurements 531
gestational immunosuppression 468
gimeracil 110
Gli (protein), Hedgehog pathway signaling on 372
Glisson, Francis (17th century) 3
glucagonomas 426
cancer therapy 433
glycoprotein(s), cell line for DISC-HSV
allogeneic 462
glycoprotein H, cell line for DISC-HSV
HCC 487–8
 treeNodeing 371
adjunctive chemotherapy 187
mitomycin with 114
cholangiocarcinoma 188
HCC, oxaliplatin with 112–13, 376, 377
(Table)
pancreatic endocrine tumors and 115
cholangiocarcinoma 333, 502
HCC incidence 52, 488
Africa 509
gene expression dysregulation 371–2
gene expression profiling, selection criterion for transplantation 284
gene therapy
HCC, adjuvant 297 (Table), 300
viral-based 361
angiotatin 408
generators
microwave thermal ablation 254
radiofrequency ablation 245, 246
Index
microwave thermal ablation 253–7
in multiblade therapy 275
radiofrequency ablation vs 255–7, 258
(Table)
mid-plane of liver 11, 12 (Fig.)
mizolam, liver transplantation 523
middle cholangiocarcinoma 328–9
middle hepatic vein 18–20, 181 (Fig.)
Milan criteria
HCC 135, 283
liver transplantation 492, 493
Milanc (radioconjugate) 132 (Table), 134
milk thistle 416
mind–body therapies 418
see also traditional alternative medical systems
mindfulness-based stress reduction (MBSR) 418
minimum procedure volumes 532
Mirizzi, Pablo 500
Mirizzi syndrome, right hepatic duct anomaly 24
Mirizzi technique 500
mitochondrial membrane proteins
apoptosis regulation 394
overexpression 396
mitogen-activated protein kinase signaling pathway, HCC 113, 385–6
mitoycin, biliary carcinoma
capcetiabine with 114
gemcitabine with 114
mixed epithelial/mesenchymal
hepatoblastoma 44
mixed hepatocellular/cholangiocarcinoma 45
mixed metastatic neoplasia,
radioembolization 136–7
MOC-31 (antibody) 42–3
model for end-stage liver disease (MELD), score 179, 288
HCC 288
Argentina 505
modified vaccinia virus (MVA) 355–6
molecular pathogenesis
HCC 368–74
see also signaling pathways
molecular targeted therapies 374–9
monoclonal antibodies
colorectal carcinoma metastases 196
see also specific drugs
mortality
cholangiocarcinoma
extrahepatic 57
intrahepatic 57
colorectal carcinoma 64
HCC
body mass index 54
from treatment 368
high-volume vs low-volume centers 532–3
mosaic vessels 409
Mozambique, HCC 510
age distribution 510
MTHH6 strain, Newcastle disease virus 356
mTOR see mammalian target of rapamycin; PI3K/
Akt/mTOR signaling pathway
mucins, intrahepatic cholangiocarcinoma 44
multiablation therapy 275
multicentric HCC 220–1
multidetector computed tomography
(MDCT) 78–9
gallbladder carcinoma 334
hilar cholangiocarcinoma resectability 326
magnetic resonance imaging compared with 90
multikinase inhibitors see sorafenib; sunitinib
multimutated herpesviruses 362–3
multiple endocrine neoplasia type 1, pancreatic
neuroendocrine tumors 426
multiple repeat liver resections
colorectal carcinoma metastases 219
HCC 222
multistage procedures, colorectal carcinoma
metastases, cost-effectiveness 535
multivisceral transplantation, neuroendocrine
tumors 432
muscularis propria, gallbladder carcinoma
invasion 337
music therapy 417–18
mutations
hepatitis B virus 515
see also specific mutations
myelomlysis, central pontine 520
myoglobin release, cryoablation 233, 235 (Table)
National Comprehensive Cancer Network
Guidelines Panel for HCC 318–19
natural history
cholangiocarcinoma 60–1
colorectal carcinoma metastases 65–7
HCC 54
necrosis
apoptosis vs 394, 395
effect of ethanol 267
radiofrequency ablation 245
transarterial embolization response 143
needle guidance, cryoablation 231
neuropathies
cryoablation injection 267–8
see also biopsy
eoadjuvant chemotherapy
colorectal carcinoma metastases 110–11, 112, 344
HCC, children 481
primary lymphoma 444
transplantation for cholangiocarcinoma
289–90
see also preoperative chemotherapy
neodymium:YAG laser 259
nephrogenic systemic sclerosis 89
neuroendocrine tumors
computed tomography 82 (Fig.)
metastases 48, 424–38
cryoablation 230, 234–6
isolated hepatic perfusion 167, 168 (Fig.)
percutaneous hepatic perfusion 169–70
radioembolization 136
radiofrequency ablation 249
transplantation for 290–1
systemic therapy 113–16
neurofibromatosis, schwannomas 442–3
neuropathy, oxaliplatin 108
neurotensin, fibromyalgia HCC 72
Newcastle disease virus 354 (Table), 356, 358
(Table)
NHANES III (survey), nonalcoholic steatohepatitis 454
nitric oxide, cholangiocarcinoma 61
nitrogen, liquid 230
nitroglycerine, low-dose infusion 523
nitrosamines, cholangiocarcinoma 59
"no-touch technique," hilar cholangiocarcinoma resection 328
nodular HCC 40
nodule, precursor lesions of HCC 40–1
nolatrexed, HCC 377 (Table)
nomenclature 11–26
liver anatomy 5, 177–8
Brisbane nomenclature 5, 11–12, 178, 194
nonendocrine tumors 424
non-Hodgkin lymphoma, AIDS 463
nonalcoholic fatty liver disease 454–5
HCC 35
nonalcoholic steatohepatitis 31, 32, 310, 454–6
nonanatomic resections 181, 183
colorectal carcinoma metastases 194
noncolorectal non-neuroendocrine
tumors 444–9
non小 cell lung cancer, molecular targeted
terapy, hazard ratios 379 (Table)
norepinephrine infusion, liver surgery 523, 524
North American staging, children 476 (Table)
nuclear medicine
imaging
hepatoblastoma 477
for internal radiotherapy 132
neuroendocrine tumors 426–7
see also positron emission tomography
99mTc-galactosyl HSA uptake test 310 (Table)
see also internal radiotherapy
NV1020, NV1034, NV1042 (multimutated
viruses) 363
obesity
gallbladder carcinoma 333
HCC 54
nonalcoholic steatohepatitis 454, 455
steatosis 31
occlusion, vascular see infiow occlusion
diotide 427–8
18Ga-labeled, PET, neuroendocrine tumors 427
HCC 112
advjuvant therapy 297 (Table), 300
18In-labeled, scintigraphy of neuroendocrine
tumors 426, 427
ocular melanoma metastases, isolated hepatic
perfusion 166–7
Okuda staging system 317, 318 (Table)
omega-3 fatty acids, for steatosis 309
oncogenes, cholangiocarcinoma 61
embolization 198, 311, 312, 314, 328
after chemotherapy 344
historical aspects 487
ethanol injection
TACE with 274
thrombosis 267
invasion
HCC 222, 283, 490
hepatoblastoma 478
MDCT venography 80
selective occlusion 311–12, 313 (Fig.)
thrombosis (PVT) 142
internal radiotherapy suitability 135
see also left portal vein
portography, catheter-assisted arterial, CT with 95–6
positioning of patient, laparoscopic liver resection 203
positron emission tomography
cholangiocarcinoma 84–5, 86 (Fig.)
colorectal carcinoma metastases 342
computed tomography with 83–5, 219
cholangiocarcinoma 86 (Fig.)
dynamic, ethanol in tumors 267
extrahepatic disease 230
galbladder carcinoma 334
neuroendocrine tumors 427
before radiofrequency ablation 249
see also 18F-fluorodeoxyglucose PET
postembolization syndrome 134, 143
postoperative complications
impact on costs 536
liver transplantation 524, 524 (Table)
postoperative morbidity, factors 523
postperfusion syndrome 524
power Doppler ultrasound 76
pravastatin, HCC 297 (Table), 300
preclinical models, molecular targeted therapies 374
precocious puberty 477
preconditioning
inflow occlusion 180, 314
pharmacologic 314
precursor lesions, HCC 40–1
pregnancy
alpha-fetoprotein 70
galbladder carcinoma 502
liver tumors 467–8
magnetic resonance imaging and 90
preload, transesophageal echocardiography 527
preoperative assessment 519–21
pregnancy 468
see also electrocardiography; perioperative cardiac assessment
preoperative catheterization of biliary tract, cholangiocarcinoma resection 186, 312, 328
preoperative chemotherapy
breast carcinoma metastases 446
colorectal carcinoma metastases 196–7
Consensus Conference on 198–9
hepatoblastoma 480
see also neoadjuvant chemotherapy
preoperative coronary revascularization 459–60
preoperative observation period, repeat resection of colorectal carcinoma metastases 219
presentation, gallbladder carcinoma, basis for therapeutic algorithm 338–9
PRETEXT system, staging in children 476, 477–8, 479 (Table)
pretransplant imaging 283
primary colorectal carcinoma, resection 342
primary sclerosing cholangitis
cholangiocarcinoma 57 (Table), 58
perihepatic 45
tumor markers and 72
transplantation 289
Pringle’s maneuver 180, 195, 314
laser thermal ablation with 261
radiofrequency ablation 248
see also inflow occlusion
prioritization, transplantation for HCC 288–9
probes
cryoablation 230, 231
gamma-emitting, neuroendocrine tumors 426
intraoperative ultrasound 78
radiofrequency ablation 246, 248
process measures, quality of care 531
prodrugs, suicide gene prodrug therapy 353
proliferation index, neuroendocrine tumor metastases 290
Prometheus 3, 4 (Fig.)
proliferative hypermethylation,
cholangiocarcinoma 61
proper hepatic artery 13, 131
left hepatic artery mistaken for 15 (Fig.)
prophylactic cholecystectomy, galbladder carcinoma 503
propofol 522
prostacycline analogs, pulmonary hypertension 520
prostate specific antigen, metastases 48
protease inhibitors 408–9
proteasome activation, drugs inhibiting 378–9
protective techniques, liver resection 308–16
protein kinase(s) 384–5
double-stranded, oncolytic therapy 355
protein kinase C 382
prothrombin time, on-site monitoring 525–7
prothrombin induced by vitamin K absence or antagonist-11 (PIVKA-11) 71, 490
prothrombin time, on-site monitoring 525–7
pulsed magnetic resonance spectrometry, nonalcoholic steatohepatitis prevalence 454
proton pump inhibitors 428
proton radiotherapy 125
pruritus
acupuncture 417
galbladder carcinoma 337
PTEN/MMAC mutations, HCC 387
PTEN mutation 374
publication of quality measurements 531
pulmonary artery catheterization, liver transplantation 523
pulmonary function, liver transplantation 521
pulmonary hypertension 520
pulse diagnosis (Chinese medicine) 415
pulsed current, radiofrequency ablation 246
pumps see implantable infusion pumps
quality adjusted life years 534
quality of care, measurement 531–3
Quattlebaum, Julian K., liver resection 5
R7020 (multimutated virus) 363
RAD001, doxorubicin with 387
radiation dose limitations
lung 135
188Re HDD-lipiodol 134
radiation exposure
liver tolerance 122, 127–8
reduction technology, MDCT 80
radiation-induced liver disease (RILD) 127, 128, 134
radiation pneumonitis 135
radiation therapy see radiotherapy
radioembolization see internal radiotherapy
radiofrequency ablation (RFA) 127, 244–53, 490–1
clinical studies 249–52
colorectal carcinoma metastases 249–51
cost-effectiveness 535
after liver resection 220
liver resection vs 251
synchronous with primary resection 228
compensated cirrhosis 284
complications 252
cryoablation vs 229, 240
ethanol ablation vs 273–4, 277, 286
costs 276
HCC 251, 321
HCC
ethanol ablation vs 251, 321
recurrent 223
liver resection vs 185
metastases 275
microwave thermal ablation vs 255–7, 258
(Table)
in multiablation therapy 275
neuroendocrine tumors 431–2, 435
transplantation, bridging therapy 251–2, 286, 287
radiofrequency-assisted hepatic resection 206
Radinomics/Valleylab system, radiofrequency ablation 247
radioisotopes
radiotherapy 126
neuroendocrine tumors 433
transarterial therapy (TART), 188Re HDD-lipiodol 134
see also nuclear medicine
radionuclides
radiosurgery see stereotactic body radiotherapy
Radiotherapeutics system, radiofrequency ablation 246–7
radiotherapy 105
colorectal carcinoma metastases 128
external beam 122–30
galbladder carcinoma 504
HCC 126–8
hepatoblastoma 480
planning 122–6
transplantation for cholangiocarcinoma 289–90
see also internal radiotherapy
rupture
adenoma 467
HCC
Africa 511
hemoperitoneum 140
hemangioma 467
S-1 (fluoropyrimidine) 110
safety
adenoviruses 360
herpesviruses 363
liver resection
after chemotherapy 197
protective techniques 308–16
saline, hot 272–3
Salmonella spp., gallbladder carcinoma 503
salvage chemotherapy, gallbladder carcinoma 345
salvage of blood, liver transplantation 523
salvage transplantation, HCC 222, 285
sarcomas
Asia 495 (Table)
post-transplant 466
primary hepatic 46–7, 459–41
undifferentiated 47, 440–1, 482
sarcomatoid HCC 47
Saudi Arabia, viral hepatitis 489
schwanomma, hepatic 442–3
scintigraphy see nuclear medicine
sclerosing cholangitis see primary sclerosing cholangitis
sclerosing HCC 42
scoring systems
liver fibrosis 33, 34 (Fig.)
tumor marker grading 69
see also model for end-stage liver disease; staging
screening, HCC 54, 71, 184, 463, 465
Asia 489–90
cost-effectiveness 534
second primaries, HCC 221
sectional arteries, hepatic 11
sectional bile ducts, anomalies 16
sectionectomies 12, 13 (Fig.), 194
laparoscopic 205, 206 (Fig.), 210
sectors, liver 177
sedation, percutaneous ethanol injection 268
seeding of tumor
biopsy 282
gallbladder carcinoma 334, 337, 504
radiofrequency ablation and 252, 286
see also peritoneal carcinomatosis
SEER Registry, cholangiocarcinoma 56
segment 3 bile duct, biliary bypass 16
segmental arteries 11
segmentectomies 12, 177, 181–3, 194
segment 1 183, 184 (Fig.)
segment 4, 3 and 2 183
segment 5 182–3
segment 6 183
segment 7 183
segment 8 181–2
segments (Couinaud) 4, 11, 14 (Fig.), 177–8
segments (Healey) 177–8
segments (liver) 22, 37
segments (Spiegelian) 11
segments (Healey) 177–8
segments (Couinaud) 4, 11, 14 (Fig.), 177–8
sections (liver) 22, 37
sections, liver 177
signs, HCC, Africa 511–12
simulation, external beam radiotherapy 122
Singapore, HCC prevention 489
dose calculation 133
sinusoids 30
endothelial cells 404
liver fibrosis 33
obstruction, cytotoxic drugs 291
SIRT therapy 355
surgical incisions 205
targeted therapies 378–8, 382–92
Wnt 61, 350, 371, 372
drug targeting 378–9, 388
signs, HCC, Africa 511–12
simulation, external beam radiotherapy 122
Singapore, HCC prevention 489
dose calculation 133
sirolimus (rapamycin) 287, 289
Kaposi sarcoma 466
transplantation for epitheloid hemangioendothelioma 291
skin, cetuximab toxicity 109
slice thickness, MDCT 78–9
small cell change, dysplastic nodules 41
small cell undifferentiated pattern, hepatoblastoma 44
small intestine, primary neuroendocrine tumors 425
smoking
cholangiocarcinoma 58
hepatoblastoma 477
Smoothed (receptor) 372
sodium, central pontine myelinolysis 520
sodium hydroxide, percutaneous 277
softness, HCC 266
somatostatin
HCC 112
neuroendocrine tumors 427
somatostatin analogs 427–8
radiolabeled, radiotherapy with 433
see also octreotide
somatostatinomas 426
sorafenib 404 (Table)
on angiogenesis 389
control arm for clinical trials 375
HCC 113, 135, 140, 287, 349, 377 (Table),
378, 385–6, 407
adjuvant therapy 300
adverse events 113
unresectable 287
South America 500–8
space of Disse 30, 31 (Fig.)
specimen extraction, laparoscopic liver resection 207
incisions 210
sphere, volume of 268
spherical ablations 246
maximum size 248
sphingomyelin transport molecules 397
Spiegelian lobe 11
spiral computed tomography 78, 83
see also multidetector computed tomography
splenic artery, selective continuous intra-arterial chemotherapy 152
split liver transplantation 6
Src (non-receptor tyrosine kinase) 383
staging 127
children 475, 476
PRETEXT system 476, 477–8, 479 (Table)
cholangiocarcinoma 43 (Table)
intrahepatic 44
perihilar 45, 328
colorectal carcinoma metastases, intraoperative laparoscopy 192
gallbladder carcinoma 49, 187, 335–6, 337–8
HCC 43, 317, 318 (Table)
hepatoblastoma 44, 477–8
Kaposi sarcoma 462
liver fibrosis 33
malignant liver tumors 43
see also Barcelona Clinic Liver Cancer staging system
staining, segmentectomy 182
standardized future liver remnant volume 198
stapler hepatectomy 206
starch microspheres 142
Starzl, Thomas E., liver transplantation 5
statins, perioperative 459
steatosis 30–2
chemical shift imaging, MRI 85
cytotoxic agents causing 197, 344
donors for transplantation 7
liver resection 308–10, 436
see also nonalcoholic fatty liver disease
Index

VIPomas 426
viral-based gene therapy 352–67
angioatin 408
virilization 477
virtual heptatectomy 80
visualization (guided imagery) 418
vitamin A derivatives, HCC, adjuvant therapy 297 (Table), 299–300, 387–8
vitamin B12-binding capacity, fibrolamellar HCC 72
vitamin K 521
Vivant Medical system, microwave thermal ablation 255
volume of liver 80, 197-8
remnant 198, 311
volume of sphere 268
volume of tumor, gross (GTV) 122
volume overload, liver surgery 523
volume-rendered MDCT 80 (Fig.)
volumetric MRI 87–8
von Recklinghausen disease, schwannomas 442–3
waiting lists for transplantation 288
on cost-effectiveness 535
dropout 286
see also bridging therapy
watersheds
blood supply to bile ducts 24
hepatic blood supply 11
wave distortion, ultrasound 76–7
WDHA syndrome (Verner–Morrison syndrome) 426
websites
complementary and alternative medicine 415
(Table)
guidelines on HCC 318, 319
wedge resections 194
repeat 216–17
see also nonanatomic resections
Weibel-Palade bodies 46
Wendell, Walter, liver resections 4
Wnt signaling pathway 61, 350, 371, 372
drugs targeting 378–9, 388
World Health Organization, grading of HCC 40
wound resection, gallbladder carcinoma surgery 503
XELIRI regimen, colorectal carcinoma metastases 108
cetuximab with 109
XELOX regimen, colorectal carcinoma metastases 108
cetuximab with 109
xenografts, drug evaluation 374
yoga 418
yttrium-90
historical aspects 131
microspheres 131–3
Y-somatostatin analogs, neuroendocrine tumors 433
ZD 6126 (vascular targeting agent) 409
Zollinger–Ellison syndrome 425, 428
zone of necrosis, radiofrequency ablation 245